Geoffrey R. Oxnard - Concepedia

Author

Geoffrey R. Oxnard

Also Known As

G Oxnard, G. Oxnard, G. R. Oxnard, G.R. Oxnard, Geoffrey Oxnard, Geoffrey R Oxnard, Geoffrey R. Oxnard, Krivoshik, Andrew

992

Publications

28.6K

Citations

H-Index

126

Concepts

All Affiliations

Dana-Farber Cancer Institute Memorial Sloan Kettering Cancer Center Foundation Medicine (United States)Harvard University Brigham and Women's Hospital

About

Geoffrey R. Oxnard is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	72	5.4K
2	Health Sciences	18	24	1.1K
3	Engineering	6	6	119
4	Education	1	1	19
5	Nursing	1	1	19

Geoffrey R. Oxnard

200

Publications

23.9K

Citations

H-Index

Page 1

	Year	Citations
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Nature Medicine Egfr T790mOncologyMedicineCancer Cell BiologyCancer Biology	2015	1.5K
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein, Annals of Oncology	2020	1.4K
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer Geoffrey R. Oxnard, Kenneth S. Thress, Ryan S. Alden, Journal of Clinical Oncology	2016	836
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, New England Journal of Medicine	2020	810
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Clinical Cancer Research	2014	772
<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman, Journal of Clinical Oncology	2016	679
Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, JAMA Oncology	2018	673
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer Lecia V. Sequist, Jean‐Charles Soria, Jonathan W. Goldman, New England Journal of Medicine	2015	660
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Clinical Cancer Research	2010	615
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay Maria E. Arcila, Geoffrey R. Oxnard, Khédoudja Nafa, Clinical Cancer Research	2011	568

Page 1